Medical Education: Jeanine M. Walenga, PhD | Loyola Medicine

Jeanine M. Walenga, PhD

Thoracic and Cardiovascular Surgery

Professor
Associate Director, Point of Care Testing,Medical Director, Clinical Coagulation Lab/Urinalysis Lab

Languages Spoken

English

Clinical Expertise

Biography

Interests

Medical Education

Medical School
Residency
Fellowship

Board Certification

Research

  • Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device McClane, N.; Jeske, W.; Walenga, J. M.; Escalante, V.; Hoppensteadt, D.; Schwartz, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. Ramacciotti, E; Castelli, V; Walenga, J; Fareed, J, International angiology : a journal of the International Union of Angiology
  • Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes. Prechel, M; Hudec, S; Lowden, E; Escalante, V; Emanuele, N; Emanuele, M; Walenga, JM, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
View All ResearchShow Less
  • Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices Jeske, W. P.; Walenga, J. M.; Menapace, B.; Schwartz, J.; Bakhos, M., Biomarkers in medicine
  • Measurement of dabigatran rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study., Harenberg, J; Du, S; Wehling, M; Zolfaghari, S; Weiss, C; Krämer, R; Walenga, J, Clinical chemistry and laboratory medicine
  • North American Thrombosis Forum AF Action Initiative Consensus Document, Ruff, C. T.; Ansell, J. E.; Becker, R. C.; Benjamin, E. J.; Deicicchi, D. J.; Mark Estes, N. A.; Ezekowitz, M. D.; Fanikos, J.; Fareed, J.; Garcia, D.; Giugliano, R. P.; Goldhaber, S. Z.; Granger, C.; Healey, J. S.; Hull, R.; Hylek, E. M.; Libby, P.; Lopes, R. D.; Mahaffey, K. W.; Mega, J.; Piazza, G.; Sasahara, A. A.; Sorond, F. A.; Spyropoulos, A. C.; Walenga, J. M.; Weitz, J. I., The American Journal of Medicine
  • Sulodexide for the extended treatment of venous thromboembolism Walenga, J. M.; Fareed, J.; Ramacciotti, E., International angiology : a journal of the International Union of Angiology
  • Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay Gerotziafas, G. T.; Rouseau, A.; Mbemba, E.; Khartechi, A.; Dreden, P. V.; Walenga, J.; Fareed, J.; Elalamy, I., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Complexes of platelet factor 4 and heparin activate Toll-like receptor 4 Prechel, M. M.; Walenga, J. M., Journal of thrombosis and haemostasis : JTH
  • Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery Matsuo, T.; Motohashi, S.; Wanaka, K.; Walenga, J. M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Anticoagulant and Antithrombotic Actions of AVE5026 an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin, Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Sustained release of tissue factor following thrombosis of lower limb trauma Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Hoppensteadt, D.; Escalante, V.; Chaudhry, T.; Jeske, W. P.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Emphasis on the Role of PF4 in the Incidence Pathophysiology and Treatment of Heparin Induced Thrombocytopenia, Prechel, M. M.; Walenga, J. M., Thrombosis journal
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer Walenga, J. M.; Lyman, G. H., Critical reviews in oncology/hematology
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S., American journal of cardiovascular disease
  • Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen Ashbrook, M.; Walenga, J. M.; Schwartz, J.; Heroux, A.; Jeske, W. P.; Escalante, V.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Prothrombin fragment 1.2 and modified antithrombin as predictors of disseminated intravascular coagulation and thrombotic risk in thermal injury Kowal-Vern, A.; Walenga, J. M.; Hoppensteadt, D.; Gamelli, R. L., Journal of burn care & research : official publication of the American Burn Association
  • A colorimetric metabolic dye reduction assay detects highly activated platelets: application in the diagnosis of heparin-induced thrombocytopenia., Prechel, M. M.; Escalante, V.; Drenth, A. F.; Walenga, J. M., Platelets
  • Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins Walenga, J. M.; Jeske, W. P.; Escalante, V.; Hoppensteadt, D.; Fareed, J.; Bakhos, M., International angiology : a journal of the International Union of Angiology
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C., Thrombosis research
  • An open label non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers., Gomes, M.; Ramacciotti, E.; Hoppensteadt, D.; Walenga, J. M.; Lewis, B.; Thethi, I.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J., Blood Coagulation & Fibrinolysis
  • Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Walenga, J. M.; Jackson, C. M.; Kessler, C. M., Seminars in Thrombosis & Hemostasis
  • Simple scoring system for early management of heparin-induced thrombocytopenia. Messmore, H. L.; Fabbrini, N.; Bird, M. L.; Choudhury, A. M.; Cerejo, M.; Prechel, M.; Jeske, W. P.; Siddiqui, A.; Thethi, I.; Wehrmacher, W. H.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • A consensus conference on complex biologics and low molecular weight heparin Kalodiki, E.; Fareed, J.; Tapson, W. F.; Hoppensteadt, D. A.; Carter, C. A.; Sussman, I.; Parker, S.; Harenberg, J.; Hull, R.; Rao, G.; Lovinger, D. F.; Reid, L. D.; Kakkar, A.; Talarico, L.; Ofosu, F. A.; Bussey, H. I.; Fanikos, J.; Groce, J. B.; Skinner, N.; Ahluwalia, M.; Iqbal, O.; Jackson, C. M.; Jeske, W. P.; Ramacciotti, E.; Van Thiel, D.; Wahi, R.; Walenga, J., International Angiology
  • Drug and dietary interactions of the new and emerging oral anticoagulants Walenga, J. M.; Adiguzel, C., International journal of clinical practice
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Laboratory methods and management of patients with heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Biology
  • Low anticoagulant heparin targets multiple sites of inflammation suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands., Rao, N. V.; Argyle, B.; Xu, X.; Reynolds, P. R.; Walenga, J. M.; Prechel, M.; Prestwich, G. D.; MacArthur, R. B.; Walters, B. B.; Hoidal, J. R.; Kennedy, T. P., American Journal of Physiology - Cell Physiology
  • Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel, M. M.; Jeske, W. P.; Walenga, J. M., Thrombosis research
  • Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. Diaz, J.; Prechel, M.; Emanuele, M.; Emanuele, N.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. Montalescot, G.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He, Z.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. Gluckman, T. J.; Segal, J. B.; Schulman, S. P.; Shapiro, E. P.; Kickler, T. S.; Prechel, M. M.; Conte, J. V.; Walenga, J. M.; Shafique, I.; Rade, J. J., Journal of Thrombosis & Haemostasis
  • Effectiveness of a clinical decision support system to identify heparin induced thrombocytopenia. Riggio, J. M.; Cooper, M. K.; Leiby, B. E.; Walenga, J. M.; Merli, G. J.; Gottlieb, J. E., Journal of Thrombosis & Thrombolysis
  • Heparin-induced thrombocytopenia: controversies and updates Walenga, J. M., eThrombosis Online Newsletter
  • Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Viskov, C.; Bouley, E.; Hubert, P.; Martinez, C.; Herman, F.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • A tribute to Professor Hans Klaus Breddin Fareed, J.; Walenga, J. M., Seminars in Thrombosis and Hemostasis
  • Antigenic (immunogenic) profiling of bovine thrombin and its purified forms. Walenga, J. M.; Bick, R. L.; Messmore, H. L., Clinical & Applied Thrombosis/Hemostasis
  • Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Fareed, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Prechel, M.; Iqbal, O.; Adiguzel, C.; Clark, M.; Litinas, E.; cunanan, J.; Linhardt, R.; Harenberg, J., Seminars in thrombosis and hemostatis
  • Differentiating low-molecular-weight heparins based on chemical biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins, Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Dr. Eberhard F. Mammen remembered. A great clinician-scientist mentor, and friend., Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Bick, R. L.; Messmore, H. L., Seminars in Thrombosis and Hemostasis
  • Heparin-induced thrombocytopenia: a serious complication of heparin therapy for acute stroke. Kawano, H.; Toyoda, K.; Miyata, S.; Yamamoto, H.; Okamoto, A.; Kakutani, I.; Walenga, J. M.; Naritomi, H.; Minematsu, K., Cerebrovascular Diseases
  • Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Untch, B. R.; Jeske, W. P.; Schwartz, J.; Botkin, S.; Prechel, M.; Walenga, J. M.; Bakhos, M., Clinical & Applied Thrombosis/Hemostasis
  • Landmarks in anti-thrombin drug development: the argatroban story. Walenga, J. M.; Bounameaux, H.; Ikeda, Y., Seminars in Thrombosis and Hemostasis
  • Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Clark, M.; Hoppensteadt, D.; Walenga, J. M.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J., International Angiology
  • Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Adiguzel, C.; Iqbal, O.; Cunanan, J.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Rivaroxaban--an oral direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia., Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M., British journal of haematology
  • The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Bick, R. L.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • The future of anticoagulation Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Fareed, J., Seminars in Respiratory & Critical Care Medicine
  • The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update Prechel, M.; Walenga, J. M., Seminars in Thrombosis & Hemostasis
  • The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia Hoppensteadt, D. A.; Walenga, J. M., Hematology - Oncology Clinics of North America
  • Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Walenga, J. M.; Drenth, A. F.; Mayuga, M.; Hoppensteadt, D. A.; Prechel, M.; Harder, S.; Watanabe, H.; Osakabe, M.; Breddin, H. K., Clinical & Applied Thrombosis/Hemostasis
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M., Current pharmaceutical design
  • Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery. Demir, M.; Duran, E.; Yigitbasi, O.; Vural, O.; Kurum, T.; Yuksel, M.; Turgut, B.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Isolation and characterization of heparin from tuna skins. Jeske, W. P.; McDonald, M. K.; Hoppensteadt, D. A.; Bau, E. C.; Mendes, A.; Dietrich, C. P.; Walenga, J. M.; Coyne, E., Clinical & Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Walenga, J. M.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J., Thrombosis research
  • Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Walenga, J. M., Clinical Advances in Hematology & Oncology
  • Why differentiate low molecular weight heparins for venous thromboembolism?. Fareed, J.; Walenga, J. M., Thrombosis Journal [Electronic Resource]
  • Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Walenga, J. M., International Angiology
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L., Clinical & Applied Thrombosis/Hemostasis
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M., Future Cardiology
  • Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Prechel, M. M.; McDonald, M. K.; Jeske, W. P.; Messmore, H. L.; Walenga, J. M., Journal of Thrombosis & Haemostasis
  • Development of generic low molecular weight heparins: a perspective Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents Walenga, J. M.; Jeske, W. P.; Fareed, J., Expert opinion on investigational drugs
  • Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal, O.; Tobu, M.; Aziz, S.; Gerdisch, M.; Da Valle, M.; Demir, M.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Fareed, J., Journal of cardiac surgery
  • Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Jeske, W. P.; Bakhos, M., Current opinion in pulmonary medicine
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Argatroban use during pediatric interventional cardiac catheterization. Cetta, F.; Graham, L. C.; Wrona, L. L.; Arruda, M. J.; Walenga, J. M., Catheterization & Cardiovascular Interventions
  • Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bacher, P.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Ahmad, S.; Untch, B.; Haas, S.; Hoppensteadt, D. A.; Misselwitz, F.; Messmore, H. L.; Walenga, J. M.; Fareed, J., Molecular & Cellular Biochemistry
  • Factor Xa inhibitors Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Methods in Molecular Medicine
  • Generic low-molecular-weight heparins: some practical considerations Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Wahi, R.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Laboratory methods for heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Monitoring the new antithrombotic drugs.[erratum appears in Semin Thromb Hemost. 2005 Apr;31(2):247] Walenga, J. M.; Hoppensteadt, D. A., Seminars in Thrombosis & Hemostasis
  • Newer insights on the mechanism of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Benefit-risk assessment of treatments for heparin-induced thrombocytopenia Messmore, H.; Jeske, W.; Wehrmacher, W.; Walenga, J. M., Drug Safety
  • Factor Xa inhibitors: today and beyond Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Current Opinion in Investigational Drugs
  • Heparin low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation, Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases. Porcelli, R.; Moskowitz, B. C.; Cetta, F.; Graham, L. C.; Godwin, J. E.; Eidem, B. W.; Prechel, M. M.; Walenga, J. M., Texas Heart Institute Journal
  • Heparin-induced thrombocytopenia paradoxical thromboembolism, and other adverse effects of heparin-type therapy, Walenga, J. M.; Frenkel, E. P.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T., Clinical pharmacokinetics
  • Emerging anticoagulant and thrombolytic drugs Iqbal, O.; Aziz, S.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Bakhos, M.; Fareed, J., Expert opinion on emerging drugs
  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Wallock, M.; Jeske, W. P.; Bakhos, M.; Walenga, J. M., Perfusion
  • The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Kowal-Vern, A.; Walenga, J. M.; McGill, V.; Gamelli, R. L., Burns
  • Antithrombin III concentrate in the acute phase of thermal injury. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L., Burns
  • Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L., Journal of Burn Care & Rehabilitation
  • Bleeding complications with glycoprotein IIb/IIIa inhibitors Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M., Drugs of today (Barcelona, Spain : 1998)